Bill > HR4837

This bill requires the Secretary of Veterans Affairs to expand an existing Veterans Health Administration (VHA) directive about informed consent to cover additional types of medications beyond opioids. Specifically, the bill directs the Secretary to update VHA Directive 1005 (originally focused on long-term opioid therapy) to also apply to five additional medication categories: antipsychotics (medications used to treat psychotic disorders), stimulants (drugs that increase activity in the central nervous system), antidepressants (medications used to treat depression), anxiolytics (drugs that reduce anxiety), and narcotics (pain-relieving drugs). The expansion of the informed consent directive would likely mean that veterans would need to receive more comprehensive written information and provide explicit consent before being prescribed these types of medications, potentially improving patient understanding and involvement in their medical treatment. The bill is designed to enhance patient safety and communication in veterans' healthcare by ensuring patients are fully informed about the potential risks and benefits of these specific medication types.